We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alliance Pharma Plc | LSE:APH | London | Ordinary Share | GB0031030819 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 35.00 | 34.85 | 35.20 | 35.10 | 34.25 | 35.00 | 391,646 | 10:21:33 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 167.42M | 936k | 0.0017 | 205.88 | 189.05M |
TIDMAPH
RNS Number : 1646G
Alliance Pharma PLC
23 November 2020
TR-1: S tandard form for notification of major holdings
Hot Features
Premium
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and
to the FCA in Microsoft Word format if possible)
1a. Identity of the issuer or the Alliance Pharma plc
underlying issuer of existing shares
to which voting rights are attached
:
---------------------------------------------------------------
1b. Please indicate if the issuer is a non-UK issuer (please mark with
an "X" if appropriate)
Non-UK issuer
------------------
2. Reason for the notification (please mark the appropriate box or boxes
with an "X")
An acquisition or disposal of voting rights X
------------------
An acquisition or disposal of financial instruments
------------------
An event changing the breakdown of voting rights
------------------
Other (please specify):
------------------
3. Details of person subject to the notification obligation
Name John Dawson (beneficial and non-beneficial
holdings)
City and country of registered office
(if applicable)
4. Full name of shareholder(s) (if different from 3.)
Name
---------------------------------------------------------------
City and country of registered office
(if applicable)
---------------------------------------------------------------
5. Date on which the threshold was 20/11/2020
crossed or reached :
---------------------------------------------------------------
6. Date on which issuer notified (DD/MM/YYYY): 20/11/2020
---------------------------------------------------------------
7. Total positions of person(s) subject to the notification obligation
% of voting % of voting rights Total of both Total number
rights attached through financial in % (8.A + of voting rights
to shares (total instruments 8.B) of issuer
of 8. A) (total of 8.B
1 + 8.B 2)
----------------------- ----------------------- ------------------ ------------------
Resulting situation
on the date
on which threshold
was crossed
or reached 5.6% 0 5.6% 532,365,082
----------------------- ----------------------- ------------------ ------------------
Position of
previous notification
(if
applicable) 6.6% 0 6.6%
----------------------- ----------------------- ------------------ ------------------
8. Notified details of the resulting situation on the date on which
the threshold was crossed or reached
A: Voting rights attached to shares
Class/type of Number of voting rights % of voting rights
shares
ISIN code (if
possible)
Direct Indirect Direct Indirect
(Art 9 of Directive (Art 10 of Directive (Art 9 of Directive (Art 10 of Directive
2004/109/EC) 2004/109/EC) 2004/109/EC) (DTR5.1) 2004/109/EC)
(DTR5.1) (DTR5.2.1) (DTR5.2.1)
---------------------
Ordinary
GB0031030819 29,976,402 - 5.6% -
-------------------- --------------------- ---------------------------------- ---------------------
SUBTOTAL 8. A 29,976,402 5.6%
------------------------------------------- ---------------------------------------------------------
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC
(DTR5.3.1.1 (a))
Type of Expiration Exercise/ Number of voting % of voting
financial date Conversion Period rights that may rights
instrument be acquired if
the instrument
is
exercised/converted.
-------------------- --------------------- ---------------------------------- ---------------------
SUBTOTAL 8. B 1
--------------------- ---------------------------------- ---------------------
B 2: Financial Instruments with similar economic effect according to
Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))
Type of Expiration Exercise/ Physical or Number of % of voting
financial date Conversion cash voting rights rights
instrument Period settlement
--------------------- --------------------- --------------- -----------------
SUBTOTAL 8.B.2
--------------- -----------------
9. Information in relation to the person subject to the notification
obligation (please mark the
applicable box with an "X")
Person subject to the notification obligation is not controlled
by any natural person or legal entity and does not control any other
undertaking(s) holding directly or indirectly an interest in the
(underlying) issuer
Full chain of controlled undertakings through which the voting rights X
and/or the
financial instruments are effectively held starting with the ultimate
controlling natural person or legal entity (please add additional
rows as necessary)
Name % of voting rights % of voting rights Total of both if
if it equals or through financial it equals or is
is higher than the instruments if it higher than the
notifiable threshold equals or is higher notifiable threshold
than the notifiable
threshold
----------------------- ---------------------- ----------------------
John Dawson (beneficial
and non-beneficial
holdings) 5.6% 5.6%
----------------------- ---------------------- ----------------------
10. In case of proxy voting, please identify:
Name of the proxy holder N/A
----------------------------------------------
The number and % of voting rights N/A
held
----------------------------------------------
The date until which the voting rights N/A
will be held
----------------------------------------------
11. Additional information
N/A
Place of completion London, UK
Date of completion 20/11/2020
-----------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
HOLBJBLTMTTTMFM
(END) Dow Jones Newswires
November 23, 2020 04:28 ET (09:28 GMT)
1 Year Alliance Pharma Chart |
1 Month Alliance Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
